Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab plus FOLFOX versus FOLFOX alone as neoadjuvant therapy for locally advanced pMMR/MSS colorectal cancer
ChiCTR2600131038Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cadonilimab, folinic acid, fluorouracil and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathological complete response rate. Started Sep 2023; status: recruiting.
02
Drugs
cadonilimabfolinic acidfluorouraciloxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600131038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131038.